In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Athenex Inc.

www.athenex.com

Latest From Athenex Inc.

Vasopressin Ruling May Greenlight More FDA Limits On Bulk Drug Compounding

By siding with the FDA against bulk compounding of vasopressin, is court encouraging more limits to Section 503B outsourcing facilities?

Manufacturing Quality

Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Financing Business Strategies

Athenex Sues FDA To Get Vasopressin On List Of Drugs That Can Be Compounded

Company argues there is a clinical need for its ready-to-use, preservative-free compounded formulation of vasopressin but agency says Vasostrict is available in a dose without the preservative.

FDA Legal Issues

Asia Deal Watch: Athenex Changes Mind, Gets Back Chinese Rights To Actinic Keratosis Candidate

Following a positive Phase III data readout for KX2-391, Athenex requests dissolution of its recent deal conferring rights to the drug in China to Chongqing Jingdong Junzhuo. TaiwanJ licenses Asian rights outside its home market for JK-122 to Newsoara.
Asia Pacific Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Alias(es)
  • Kinex Pharmaceuticals Inc.
  • Kinex Pharmaceuticals LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Athenex Inc.
  • Senior Management
  • Johnson Lau, MD, Chmn. & CEO
    Randoll Sze, CFO
    Rudolf Kwan, MD, CMO
    Simon Pedder, PhD, Chief Bus. & Strategy Officer
    Jeffrey Yordon, COO
    David Cutler, MD, VP, Clinical Dev.
  • Contact Info
  • Athenex Inc.
    Phone: (716) 427-2950
    1001 Main St.
    Ste. 600
    Buffalo, NY 14203
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register